Longitudinal assessment of real-world patient adherence: a 12-month electronic patient-reported outcomes follow-up of women with early breast cancer undergoing treatment
Supportive Care in Cancer · 2024
DOI: 10.1007/s00520-024-08547-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Pimrapat Gebert und 4 weiteren Autor:innen. Beteiligte Einrichtung: Berlin Institute of Health at Charité -Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Breast Neoplasms, Patient Reported Outcome Measures, Patient Compliance, Quality of Life. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charité - Universitätsmedizin Berlin.
Abstract (Originalsprache)
Background
Electronic patient-reported outcomes (ePROs) assess patients’ health status and quality of life, improving patient care and treatment effects, yet little is known about their use and adherence in routine patient care.
Aims
We evaluated the adherence of invasive breast cancer and ductal carcinoma in situ (DCIS) patients to ePROs follow-up and whether specific patient characteristics are related to longitudinal non-adherence.
Methods
Since November 2016, the Breast Center at Charité – Universitätsmedizin Berlin has implemented an ongoing prospective PRO routine program, requiring patients to complete ePROs assessments and consent to email-based follow-up in the first 12 months after therapy starts. Frequencies and summary statistics are presented. Multiple logistic regression models were performed to determine an association between patient characteristics and non-adherence.
Results
Out of 578 patients, 239 patients (41.3%, 95%CI: 37.3–45.5%) completed baseline assessment and all five ePROs follow-up during the first 12 months after therapy. On average, above 70% of those patients responded to the ePROs follow-up assessment. Adherence to the ePROs follow-up was higher during the COVID-19 pandemic than in the time periods before (47.4% (111/234) vs. 33.6% (71/211)). Factors associated with longitudinal non-adherence were younger age, a higher number of comorbidities, no chemotherapy, and a low physical functioning score in the EORTC QLQ-C30 at baseline.
Conclusions
The study reveals moderate adherence to 12-month ePROs follow-up assessments in invasive early breast cancer and DCIS patients, with response rates ranging from 60 to 80%. Emphasizing the benefits for young patients and those with high disease burdens might further increase adherence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Berlin Institute of Health at Charité -Universitätsmedizin Berlin, Berlin, Germany.
- Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Department of Gynecology With Breast Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Department of Gynecology With Breast Center, Charité - Universitätsmedizin Berlin, Berlin, Germany. maria-margarete.karsten@charite.de.
Förderung
- Charité - Universitätsmedizin Berlin
Zitieren
APA
Gebert, P., Hage, A. M., Blohmer, J. U., Roehle, R., & Karsten, M. M. (2024). Longitudinal assessment of real-world patient adherence: a 12-month electronic patient-reported outcomes follow-up of women with early breast cancer undergoing treatment. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08547-7
Vancouver
Gebert P, Hage AM, Blohmer JU, Roehle R, Karsten MM. Longitudinal assessment of real-world patient adherence: a 12-month electronic patient-reported outcomes follow-up of women with early breast cancer undergoing treatment. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08547-7
BibTeX
@article{Gebert2024,
author = {Gebert, Pimrapat and Hage, Anna Maria and Blohmer, Jens-Uwe and Roehle, Robert and Karsten, Maria Margarete},
title = {Longitudinal assessment of real-world patient adherence: a 12-month electronic patient-reported outcomes follow-up of women with early breast cancer undergoing treatment},
journal = {Supportive Care in Cancer},
year = {2024},
doi = {10.1007/s00520-024-08547-7}
}
EUVIMED